Dr Tom's doesn't matter for FDA review. NWBO (and Dr. Liau) chose PFS as the primary endpoint. Who cares what Dr. Tom's thinks, it was what NWBO picked and they stuck too it until they saw they failed to meet the endpoint. Dr. Liau confirmed it as the primary endpoint in her 2018 journal publication. And NWBO didn't announce all the changes until their 3/22 SEC 10K filing when they tossed out the PFS primary endpoint and replaced everything in the trial AFTER data was unblinded.
Market Data 
Markets 
AI
